Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tiziana Life Sciences Ltd. (NASDAQ: TLSA) SEC filings page provides access to the company’s official regulatory disclosures as a foreign private issuer. Tiziana files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings include press releases and formal updates on clinical, regulatory, and corporate developments.
For investors analyzing Tiziana’s clinical-stage biopharmaceutical business, Form 6-K reports are particularly important. Recent 6-Ks have furnished announcements about the dosing of the first patient in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, the initiation of enrolment for that trial, and the inclusion of the company’s ALS Phase 2 study in the ALS MyMatch Program. Other 6-K filings describe insider share purchases by the Chief Executive Officer, the withdrawal of a proposed public offering of common shares due to market conditions, interim financial results and corporate updates on lead programs, and participation in global healthcare conferences.
Tiziana also reports on safety and regulatory interactions for intranasal foralumab, including Development Safety Update Reports submitted to the U.S. Food and Drug Administration that summarize cumulative exposure and serious adverse event findings across neuroinflammatory indications. While these safety reports themselves are submitted to regulators, related information may be discussed in filed or furnished documents.
On this page, users can review Tiziana’s 20-F annual report for a comprehensive overview of its business and risk factors, and track ongoing 6-K filings for timely information on clinical milestones, strategic plans such as the intended spinout of IL-6 asset TZLS-501, and capital markets activities. Stock Titan enhances these filings with AI-powered summaries that explain key points from lengthy documents, highlight material disclosures, and make it easier to understand how each filing may relate to Tiziana’s intranasal immunotherapy programs and overall corporate strategy.
Tiziana Life Sciences reported new biomarker data for its lead candidate, intranasal foralumab, in non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA). In 10 patients, 14 paired assessments linked treatment to reduced cerebrospinal fluid (CSF) inflammation, increased neuroprotective proteomic pathways, and reduced microglial activation on [F-18]PBR06-PET scans.
Investigators described this as the first direct connection between PET changes and favorable CSF shifts during nasal foralumab treatment in this population, supporting its role in targeting smoldering CNS inflammation. Tiziana is running an ongoing randomized, double-blind, placebo-controlled Phase 2a trial in na-SPMS, with top-line data expected in the first half of 2026, and has dosed 14 expanded-access patients, all showing disease improvement or stability within 6 months.
Tiziana Life Sciences Ltd. is offering 8,800,000 common shares at $1.25 per share on a best efforts basis, with one warrant for each share. Each warrant allows the holder to buy one additional common share at $1.50 until July 16, 2026. The offering would generate gross proceeds of $8,800,000, and the company plans to use the funds, together with existing cash, primarily to complete Phase 2 clinical trials in non-active SPMS and MSA and to support broader development of its lead asset, foralumab.
Common shares outstanding are expected to be 127,259,131 after the offering, up from 118,851,954 as of June 30, 2025. The company highlights that investors will experience immediate dilution, estimating a $1.11 per-share dilution relative to adjusted net tangible book value. Management also notes its status as an emerging growth company and smaller reporting company, ongoing need for additional capital, and the historically volatile trading range of its Nasdaq-listed shares under the symbol TLSA.
Tiziana Life Sciences Ltd. is conducting a primary offering of 8,800,000 common shares at $1.25 per share, with each share paired with a warrant to buy one additional common share at $1.50 until July 16, 2026. The shares trade on Nasdaq under the symbol “TLSA”.
Gross proceeds are expected to be $8.8 million before expenses, and the company plans to use the cash, together with existing funds, mainly to complete its Phase 2 clinical trials in non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA), and to support broader development of its lead drug foralumab and general corporate purposes. After the offering, Tiziana expects to have 127,259,131 common shares outstanding, so new investors will experience immediate dilution relative to net tangible book value and could face further dilution if warrants, options, or RSUs are exercised.
Tiziana Life Sciences filed a Form 6-K to highlight the peer-reviewed publication of its open-label study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The study appears in Neurology Neuroimmunology & Neuroinflammation, a journal of the American Academy of Neurology, and reports comprehensive positive results previously shared on May 6, 2025.
The publication is described as the first na-SPMS study to integrate TSPO-PET imaging, proteomics, and clinical assessments, supporting a novel mechanism for targeting progression independent of relapse activity. Investigators note clinical stabilization, microglial PET findings, and biomarker changes that align with nasal foralumab’s proposed immune-modulating effects without broad systemic immunosuppression.
Foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, has been dosed intranasally in 14 na-SPMS patients under an expanded access program, with improvement or stability within six months in all patients. Tiziana is also running an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS, with top-line data expected in the first half of 2026.
Tiziana Life Sciences Ltd closed a company-led registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising gross proceeds of $8.8 million. Each share includes one warrant to buy an additional ordinary share at $1.50, exercisable until July 16, 2026, for potential additional gross proceeds of about $10.56 million. The financing was conducted without an underwriter and was taken up by senior management and existing shareholders, including the CEO, who purchased 2,400,000 shares, and the Executive Chairman, who purchased 1,600,000 shares through an affiliated entity. The company states that the proceeds will enable it to complete its Phase 2 na‑SPMS and MSA clinical trials and reach top-line data readouts.
Tiziana Life Sciences Ltd. is conducting a primary offering of common shares on a best efforts basis at $1.25 per share. For every common share purchased, investors receive one warrant to buy an additional common share at $1.50 at any time up to July 16, 2026.
The company estimates net proceeds of about $6.5 million, with no placement agent fees, to be used mainly to fund clinical development of its lead drug foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, plus working capital and general corporate purposes. Tiziana notes this financing will not be enough to complete its clinical programs and that further capital will be required.
As of June 30, 2025, the company had 118,851,954 common shares outstanding. The filing highlights risks including immediate dilution to new investors, potential share price volatility, and dependence on future financings to support ongoing trials and operations.
Tiziana Life Sciences is raising
The company states that the proceeds will enable completion of its Phase 2 clinical trials in non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA) and support topline data readouts. The financing was led by Tiziana’s CEO, who bought 2,400,000 shares, and the Executive Chairman and Founder, who bought 1,600,000 shares through an affiliated entity, increasing their shareholdings significantly.
Tiziana Life Sciences Ltd filed a Form 6-K to share that CEO Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum in San Francisco at 2:00 PM PT on January 11, 2026, during J.P. Morgan Healthcare Conference Week. Senior management will also attend for one-on-one meetings with investors, partners, and other stakeholders.
The presentation will focus on Tiziana’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions. The company reports that 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program showed improvement or disease stability within 6 months, and intranasal foralumab is also being studied in a Phase 2a randomized, double-blind, placebo-controlled trial.
Tiziana Life Sciences reported that Founder and Executive Chairman Gabriele Cerrone will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York, on December 17, 2025. The ceremony, held from 3:45 PM to 4:15 PM ET, celebrates the company’s ongoing work on intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered through the nose. This lead candidate and its nasal delivery approach aim to improve efficacy, safety, and tolerability versus traditional intravenous methods for neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer’s disease, and ALS.
Tiziana Life Sciences LTD reported that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. This milestone comes shortly after enrollment began, when the first patient was expected to be dosed imminently. The Phase 2 study is evaluating intranasal foralumab both as a standalone treatment and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab in early Alzheimer’s patients.